Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
Despite recent advances, most patients with advanced colorectal cancer continue to have a
poor prognosis. 5-FU, leucovorin, oxaliplatin and bevacizumab is a standard treatment option
for patients with stage IV colorectal cancer. Fluorouracil (5-FU), leucovorin and oxaliplatin
are considered traditional chemotherapies that try to stop tumor growth by affecting how they
divide. Bevacizumab is a therapy to try to block the blood vessels that tumors need to grow.
It is considered a 'targeted agent'. Erlotinib is another targeted agent, that has been shown
to be effective in treating lung and other cancers. This trial is assessing the potential
benefit of adding these second targeted agents to standard treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Genentech, Inc. Massachusetts General Hospital Sanofi-Synthelabo